Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Longitudinal trajectories of cognitive, functional, and neuropsychiatric decline in Alzheimer's disease during COVID-19 lockdown in South Korea.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • الموضوع:
    • نبذة مختصرة :
      Competing Interests: Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: This study was approved by the Institutional Review Board (IRB) of Seoul National University Boramae Medical Center (Approval Number: 10-2020-295). The requirement for informed consent was waived due to the retrospective nature of the study, as all data were anonymized and de-identified prior to analysis. The study adhered to the principles of the Helsinki Declaration.
      The progression of Alzheimer's disease (AD) and its interaction with COVID-19-induced social isolation remains poorly understood. This study investigated the longitudinal trajectories of AD severity on cognitive function, functional ability, and neuropsychiatric symptoms, and examined the impact of COVID-19 lockdown on AD patients in South Korea. In this retrospective longitudinal study, data from 253 adults (aged ≥ 55) diagnosed with mild cognitive impairment (MCI) or AD were analyzed, collected between 2018 and 2022. Participants were classified into four groups based on clinical dementia rating (CDR) scores: MCI, AD-CDR0.5, AD-CDR1, and AD-CDR2. Cognitive function, functional abilities, neuropsychiatric symptoms, depressive symptoms, and overall dementia severity were assessed. Linear mixed-effects models, along with mediation and moderation analyses were employed to analyze the data. Significant trajectories of decline in cognitive function and functional abilities were observed over time, with more pronounced declines in higher AD severity groups. The COVID-19 lockdown exacerbated cognitive decline and impairment in activities of daily living (ADL) specifically in the most severe AD group (AD-CDR2). Instrumental activities of daily living (IADL) mediated the relationship between mini-mental state examination (MMSE) scores and CDR sum of boxes (CDR-SB) in the MCI, AD-CDR0.5, and AD-CDR1 groups. A significant interaction between MMSE scores and neuropsychiatric symptoms was observed in the moderate AD group (AD-CDR1), indicating that worsening neuropsychiatric symptoms intensified cognitive decline. Neuropsychiatric Inventory (NPI) scores increased over time, indicating worsening neuropsychiatric symptoms, whereas depressive symptoms, measured by the short geriatric depression scale (SGDS), remained stable over the study period. This study highlights the impact of AD severity on cognitive and functional decline, further exacerbated by the COVID-19 lockdown. The mediating role of IADL suggests that maintaining complex daily activities may be crucial in slowing disease progression in AD patients. Additionally, the worsening of neuropsychiatric symptoms underscores the need for targeted mental health support, especially during periods of social isolation, to mitigate adverse effects on patients and caregivers.
      (© 2025. The Author(s).)
    • References:
      J Psychosom Res. 2004 Sep;57(3):297-305. (PMID: 15507257)
      Alzheimers Dement. 2018 Apr;14(4):535-562. (PMID: 29653606)
      Appl Neuropsychol. 2007;14(3):208-14. (PMID: 17848131)
      J Alzheimers Dis. 2020;76(1):41-47. (PMID: 32568211)
      Alzheimers Res Ther. 2015 Mar 18;7(1):17. (PMID: 25815063)
      Front Psychiatry. 2020 Sep 09;11:578015. (PMID: 33033486)
      Neurodegener Dis Manag. 2012 Oct 1;2(5):483-491. (PMID: 23585777)
      J Alzheimers Dis. 2024;100(2):563-578. (PMID: 38875031)
      Neuropsychiatr Dis Treat. 2024 Mar 26;20:689-696. (PMID: 38559771)
      Lancet. 2020 Aug 8;396(10248):413-446. (PMID: 32738937)
      Alzheimers Dement. 2020 Nov;16(11):1571-1581. (PMID: 32789951)
      Nat Hum Behav. 2023 Aug;7(8):1307-1319. (PMID: 37337095)
      Neurology. 1984 Jul;34(7):939-44. (PMID: 6610841)
      J Affect Disord. 2024 Jan 1;344:407-413. (PMID: 37848087)
      Front Neurol. 2023 Aug 17;14:1208802. (PMID: 37669257)
      Ageing Res Rev. 2015 Jul;22:39-57. (PMID: 25956016)
      J Alzheimers Dis. 2024;98(1):75-78. (PMID: 38393917)
      Neurology. 2018 Jan 16;90(3):126-135. (PMID: 29282327)
      Md State Med J. 1965 Feb;14:61-5. (PMID: 14258950)
      Lancet. 2021 Apr 24;397(10284):1577-1590. (PMID: 33667416)
      Dis Model Mech. 2022 May 1;15(5):. (PMID: 35521689)
      Medicine (Baltimore). 2021 Oct 8;100(40):e27416. (PMID: 34622849)
      PLoS One. 2018 Aug 17;13(8):e0201008. (PMID: 30118489)
      J Korean Med Sci. 2000 Dec;15(6):609-15. (PMID: 11194184)
      J Gerontol B Psychol Sci Soc Sci. 2002 Jan;57(1):P47-53. (PMID: 11773223)
    • Contributed Indexing:
      Keywords: Alzheimer’s disease; COVID-19 lockdown; Cognitive decline; Functional ability; Neuropsychiatric symptoms
    • الموضوع:
      Date Created: 20250308 Date Completed: 20250512 Latest Revision: 20250512
    • الموضوع:
      20250512
    • الرقم المعرف:
      PMC11890767
    • الرقم المعرف:
      10.1038/s41598-025-92497-5
    • الرقم المعرف:
      40057581